NanoScope Therapeutics Receives U.S. Patent for Vision-Restoring Multi-Characteristic Opsin Technology
NanoScope Therapeutics announced that the U.S. Patent and Trademark Office has granted U.S. Patent No. 12,459,977 for its proprietary Multi-Characteristic Opsin (MCO) optogenetic platform, providing broad intellectual property protection for methods to restore vision in patients with retinal degenerative diseases such as retinitis pigmentosa, Stargardt disease, and geographic atrophy. The patent strengthens the company’s global IP position through 2039 and supports the continued advancement of its MCO-based therapeutic programs aimed at restoring light sensitivity in patients with photoreceptor loss. 
NanoScope Therapeutics Receives U.S. Patent for Vision-Restoring Multi-Characteristic Opsin Technology